New therapeutics offer some hope in this emerging market.
The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.
There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.
Clinicians review a patient case including diagnosis, treatment, and follow-up.
The prevalence of this disease in this patient population is much higher than in the general public.
In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.
The limitation in the number of pediatric-specific guidelines by professional organizations, and results from large randomized clinical trials, may place an additional emphasis on literature evaluation skills for pediatric ASP pharmacists.
Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
Drs Jacinda Abdul-Mutakabbir, Madeline King, Rodney Rohde, and expert nurse practitioner Wendy Wright provide insight on receiving the influenza vaccine concurrently with the SARS-CoV-2 booster shot, and comment on data on immune responses from the Moderna and Pfizer/BioNTech vaccines.
Research finds that individuals who received a COVID-19 vaccine more recently were less likely to develop long COVID.
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
This market has seen a flurry of activity, as shown by a review of the latest agents.
The key is using the right dose on the right patient at the right time.
The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Emerging treatment options for patients with persistently positive blood cultures with Methicillin-Susceptible Staphylococcus aureus (MSSA).
Outside of vaccines, these underutilized therapies are the best defense against severe disease.
New 21-valent conjugate vaccine authorized to combat invasive pneumococcal disease and pneumonia in individuals aged 18 and older.
The latest article from SIDP illustrates the challenges of area under the curve (AUC) implementation and offers insights for strategies and resources to overcome them.
New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention
Biocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
Conflicting priorities of infection control, antimicrobial stewardship, and critical care make the management of sepsis secondary to SARS-CoV-2 infection challenging.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Combining over 1,000 human antibodies, GIGA-2339 aims to achieve viral clearance and activate the immune system, offering a potential solution where current therapies fall short of providing a cure.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
Here is a review of the literature for this class of antibiotics.
Although COVID-19 vaccination remains the primary focus for health care, other paramount vaccines need to be recognized. Here is a review.
Four lessons learned from the AIDS crisis that can be applied to the fight against our current pandemic.
While the COVID-19 pandemic has helped advance respiratory diagnostics and surveillance, there are still many gaps that remain across the spectrum of healthcare.